Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Myriad Genetics, Inc.

< Previous 1 2 3 4 5 6 Next >
News headline image
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers LH MYGN
News headline image
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN SOPH
News headline image
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Names Raj Jampa as New Chief Technology Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Commercially Launches Precise MRD with Select Community Oncologists
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
News headline image
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
Tickers MYGN
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.